2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

6008 Donor DNMT3A mutations impact dynamics of immune reconstitution in allogeneic stem cell transplant recipients

Francesco Malfona, MD, PhD, Kevin Panaro2, Casey Gervais3, Kyle Hebert, MSc4, Naomi Kawashima5, Carol Reynolds6, Roman Shapiro, MD7, Nicoletta Cieri, MD, PhD8, Nuttavut Sumransub, MD9, Remy Dulery, MD, PhD10, Sarah Nikiforow, MD, PhD11, Mahasweta Gooptu, MD12, Amar Harry Kelkar, MD, MPH13, John Koreth, MD,MBBS,PhD,DPhil14, Rizwan Romee, MD15, Corey Cutler, MD,FRCPC,MPH16, Joseph Antin, MD17, Vincent Ho, MD18, Catherine J. Wu, MD19, Robert J Soiffer, MD20, R. Coleman Lindsley, MD, PhD21, Jerome Ritz, MD22
1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
5 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
6 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
8 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
9 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
10 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
11 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
12 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
13 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
14 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
15 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
16 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
17 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
18 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
19 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
20 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
21 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
22 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Dysregulated immune reconstitution (IR) after allogeneic hematopoietic stem cell transplant (HCT) plays a key role in determining post-HCT outcomes. In a previous study, Gibson et al. (JCO 2022) reported that >20% of donors ≥40 years of age harbored clonal hematopoiesis (CH)-associated mutations, and 85% of donor CH clones engrafted in HCT recipients. The epigenetic regulator DNMT3A (DNMT3A-CH) is the most commonly mutated gene in CH. Recipients of DNMT3A-CH with VAF ≥1% who received calcineurin inhibitors for GVHD prophylaxis -but not those receiving post-HCT cyclophosphamide- had a higher incidence of chronic GVHD (cGVHD) and reduced relapse risk.

To examine whether CH influenced IR in patients within the Gibson et al. cohort, we monitored recovery of T, B, NK and dendritic cells (DC) by flow cytometry at serial time points for 1 year (12M) after HCT (N=726 samples). Results in 61 patients with DNMT3A-CH were compared to 111 patients without CH (No-CH) matched for age at HCT, primary disease, disease status, D-R sex match, D-R HLA match, D-R CMV serostatus, conditioning intensity and GVHD prophylaxis, transplanted at the Dana-Farber Cancer Institute between 2005 and 2019. Median patient age at HCT was 57.9 (range 30.9-68.3) in the DNMT3A-CH group and 56.4 (range 26.9-75.4) in the No-CH group. The most common primary disease were acute myeloid leukemia (34% and 38% in DNMT3A-CH and No-CH, respectively). Donors in the DNMT3A-CH group were older (median 55.3 vs 52.8 years) and recipients more often CMV-seropositive (median 57% vs 48%). Patients receiving post-HCT cyclophosphamide were excluded.

Recovery of absolute lymphocyte counts, total T cells (CD3+) and CD4 T cells was similar in both groups. Patients with DNMT3A-CH had higher CD8+ T cell counts from 2M to 12M vs No-CH, but with significance only at 2M (CD8 at 2M: 103/μL vs 53/μL, p=0.01), due to expansion of CCR7+ CD45RA- central memory (CM) and CCR7- CD45RA- effector memory (EM) subsets, and higher numbers of CCR7+ CD45RA+ naïve cells at 6M (p=0.03). CD8 T cells showed higher PD1 expression compared to No-CH, especially in CM at 2M (65% vs 56%, p=0.003). CD19+ B cells, CD56+ CD3- NK cells, NK-cell subsets and CD11c+ myeloid DCs recovered similarly in both groups, but recovery of CD123+ plasmacytoid DCs was significantly higher in DNMT3A-CH vs No-CH at 2M, 3M, 6M and 12M.

To further examine T cell reconstitution associated with DNMT3A-CH and the development of cGVHD, we applied a 30-marker spectral flow cytometry panel focusing on functional T cell markers to characterize peripheral T cells at 6M comparing 3 groups: 9 patients with DNMT3A-CH who subsequently developed cGVHD; 9 patients with No-CH who subsequently developed cGVHD (No-CH+cGVHD) -to isolate the effect of the DNMT3A-CH on the development of cGVHD; and 6 patients with No-CH who did not develop cGVHD (No-CH-No-cGVHD). FlowSOM clustering on gated CD4 and CD8 T cells identified 9 clusters in both subsets (CD4-C1-9; CD8-C1-9) with distinctive marker expression. CD4-C2 and CD4-C3 were enriched in DNMT3A-CH vs No-CH+cGVHD (p=0.03 and p=0.02, respectively). Both clusters comprised cytotoxic CD4 T cells at different maturation levels (GzmB+ CD57+ or CD57-) with early effector to memory phenotype. An additional cluster of naïve CD4 T cells (CXCR3+ CD27+ CD95-) was enriched in No-CH-No-cGVHD patients. Within CD8 T cells, CD8-C3 and CD8-C4 were enriched in DNMT3A-CH vs No-CH+cGVHD (p=0.03 and 0.01, respectively). CD8-C3 comprised an early effector subset (CCR7+ CD45RA+ CD27- CD95- CX3CR1+ KLRG1+ CD127- Granzyme B+ CD57+) and CD8-C4 represents a highly cytotoxic terminally differentiated subset (CCR7- CD45RA+ CX3CR1+ KLRG1+ CD127- Granzyme B+ CD57+). In contrast, CD8-C9, representing a precursor-to-intermediate exhausted central memory subset (CD45RA- CCR7+ PD1+ TIGIT+/- TIM3+ CD27+ ki67+/- Granzyme B+/-CD57-) was predominant in No-CH+cGVHD vs both DNMT3A-CH (p=0.01) and No-CH-No-GVHD (p=0.04). These findings highlight CD4 and CD8 T cells with higher cytotoxic states and less exhaustion along with increased plasmacytoid DCs in patients with DNMT3A-CH who later develop cGVHD and implicate the impact of donor CH on immune recovery after allo-HCT. Focusing on these effector T cell subsets and plasmacytoid DCs, more detailed characterization including functional studies are needed to identify mechanisms whereby engraftment of donor stem cells with DNMT3A-CH can enhance alloreactivity in patients after HCT.

Francesco Malfona, MD, PhD: No relevant conflicts of interest to declare.